IGF-1 LR3 Pre-Research Checklist

A pre-research checklist for IGF-1 LR3 is a sourcing and documentation audit you complete before the purchase order goes out — not after the box lands. Five things get confirmed: compound identity against a batch-specific certificate of analysis, the breadth of the testing panel behind that certificate, storage and transit handling, research-use-only labeling and terms, and the supplier's commercial terms including published pricing, minimum order quantities and lead times. For a business buyer, this is a supplier-risk exercise rather than a bench exercise. If any item on the list is unavailable to you before payment clears, that absence is itself the finding.

Why the first items have nothing to do with the vial

Most checklists circulating in this category are written for someone running an assay. That is not the problem a med spa owner, clinic operator, telehealth founder or reseller is solving. Your exposure sits upstream: you are committing capital to inventory you cannot visually inspect for identity or purity, from a supplier whose quality system you have to take on documentation alone.

So the checklist front-loads paperwork. Before a compound is worth evaluating on its science, the supplier has to be worth evaluating on its records. Can you see a certificate of analysis tied to the specific lot you would receive, before you buy? Is the testing panel described, or just asserted? Is pricing published, or does it appear only after a sales call? Does the supplier state a fulfillment window and hold to it?

These questions screen out a surprising share of the market in a single pass. A supplier that will not show batch documentation until money has moved has told you how it handles a bad batch. A supplier whose pricing exists only inside a quote has told you that your cost depends on how hard you negotiate rather than how much you order. Neither is a workable foundation for a catalog you plan to restock.

What the compound is on a specification sheet

IGF-1 LR3 — Long R3 insulin-like growth factor-1 — is an engineered analog of IGF-1. Where native IGF-1 is a 70-residue polypeptide, the LR3 variant carries an arginine substitution at position 3 and a 13-residue extension at the N-terminus, giving an 83-residue sequence of roughly 9 kDa. Those two modifications are the entire reason the analog exists: published in-vitro work reports substantially reduced affinity for IGF binding proteins compared with native IGF-1, which is why the analog appears as a supplement in cell-culture systems where binding-protein interference complicates interpretation.

That is the compound-science level, and it is where a buyer should stop. Nothing about this analog's behavior in culture translates into a claim you can make, and no legitimate supplier will hand you one. Research-use-only means the material is sold for laboratory investigation and is not an approved drug, not for human consumption, and not accompanied by use guidance of any kind.

What the specification sheet gives you commercially is a verification target. You now know what a correct certificate should say: the stated sequence, the expected molecular weight, the analog designation rather than a vague family name. A certificate that identifies a product only by trade name, with no sequence and no mass confirmation, has not demonstrated that the vial contains what the label claims. Identity precedes purity — a 99% pure sample of the wrong molecule is still the wrong molecule.

Reading a certificate of analysis without taking it on faith

Certificates vary enormously in what they actually prove. Use a fixed read pattern so you are comparing suppliers on the same axis every time.

The last row is the one buyers skip and later regret. A certificate you can only obtain after committing funds is a marketing asset, not a quality control. The same applies to a single reference certificate reused across every lot: batch testing means each production run is tested, and the document you receive corresponds to the material in your hand. Ask which of the two you are being shown.

One more discipline worth building in: keep the certificate on file against the lot number for as long as you hold the inventory. If a question ever arises about a specific unit, traceability back to a dated document is the only answer that holds up.

Storage, cold chain, and the part of the order you do not control

Lyophilized peptide material is sensitive to heat, humidity and light, and the portion of its life you have least visibility into is transit. So the checklist includes questions about logistics that have nothing to do with chemistry: how is the material packed, what shipping method is used, who is responsible if a shipment is delayed in a hot facility over a weekend, and what the supplier's policy is when a package arrives compromised.

Domestic fulfillment matters here for a practical reason rather than a patriotic one. Shorter routes mean fewer handoffs, fewer customs holds, and fewer days during which a package sits somewhere you cannot see. International drop-shipping arrangements can work, but they add variables you cannot audit, and they make it harder to establish when in the chain a problem occurred.

On your side, confirm before the first order that you have appropriate storage capacity and a receiving process that gets material put away promptly rather than left on a counter. Log lot numbers at intake. None of this is exotic — it is ordinary inventory control — but it is the difference between a supply issue you can diagnose and one you can only argue about.

The compliance questions that belong with your attorney

This section is informational and is not legal advice. The honest position is that the regulatory picture for research-use-only compounds is layered — federal framework, state-level rules, professional licensing boards, and in some cases local business licensing — and the specifics turn on facts about your business that no article can know.

What a checklist can do is tell you which questions to bring to counsel. Ask: under what circumstances, if any, may my business purchase and hold research-use-only materials? Does my license type, or my staff's, change that answer? What are the rules governing how I may describe or market materials I resell, and what representations would create exposure? If I plan to private-label, who is treated as the responsible party for labeling? What recordkeeping would a regulator expect to see if it asked? And what must my customer-facing terms say about research use?

Take those questions to a licensed attorney in your jurisdiction and to your state board before you commit to a category. Do not take a supplier's regulatory reassurance as a substitute — a supplier can describe its own testing and documentation, which is a factual matter, but it cannot resolve your compliance posture, which is a legal one. Any vendor that tells you what you are permitted to do with the material has stepped outside what it can responsibly answer.

Supplier terms are half the checklist

The commercial side deserves the same rigor as the documentation side, because it determines whether you can actually run a catalog rather than a series of one-off purchases.

Start with pricing visibility. Tiered wholesale pricing you can read before applying lets you model cost at different volumes. Pricing that materializes only after a discovery call usually means price is a function of negotiation rather than volume, which makes planning impossible and renewal pricing unpredictable.

Then minimum order quantities and reorder behavior. The question is not only what the minimum is but whether it is stable, and whether the same compound will be available at the same specification in ninety days. Batch-to-batch consistency is a procurement issue as much as a quality one — inconsistent supply forces substitutions you did not plan.

Resist the temptation to build a business case on borrowed numbers. Margin, markup and payback timelines in this category vary widely with volume, category mix, your own operating costs and how you position your catalog. Any figure quoted to you as typical should be treated as marketing until you have modeled it against your own costs. A supplier that leads with profit projections rather than documentation is selling the wrong thing.

Finally, assess responsiveness before you need it. Send a documentation question pre-application and see what comes back. The quality and speed of that answer is a reasonable proxy for what happens when a shipment goes sideways.

What Real Peptides does differently

Real Peptides builds its Wholesale Partner Program around the items this checklist asks for, as a matter of program design rather than positioning.

Compounds are tested to 99%+ HPLC purity, and each batch runs through a seven-panel test rather than a single purity check — the panel reaches past purity into the contaminant and identity questions a purity percentage alone cannot answer. Certificates of analysis are publicly verifiable: a prospective buyer can read the lab results before applying, without a sales call and without paying for the document, and can match a certificate to the batch received. That is the opposite of the pattern where COAs are withheld, charged for, or recycled across production runs.

Fulfillment is domestic, with orders shipping in five to seven days — short enough to keep transit variables manageable and predictable enough to plan reorders around. Wholesale access runs through a three-step application rather than an open checkout, which keeps the program to qualified business buyers.

The catalog is organized by research area rather than by hype, and every compound in it is sold research-use-only, with no dosing, preparation or administration guidance provided — that boundary is absolute regardless of who asks.

Running the list before the next purchase order

Work the checklist in order: identity, certificate, testing panel, logistics, compliance questions for counsel, then commercial terms. Suppliers that clear all six are a smaller group than the search results suggest. If you are a med spa, clinic, telehealth business or reseller ready to evaluate a supplier against these criteria, the Wholesale Partner Program application is the next step, and the documentation you would be auditing is already published for you to check first.

Buyers running this audit for the first time usually start with the documents rather than the marketing copy — the Growth Factor & Tissue Signaling Research and Performance & Recovery Research collections show how the catalog is organized by research area, while individual listings such as CJC-1295 No DAC 10mg, Ipamorelin 10mg, Tesamorelin 10mg and BPC-157 10mg show the batch documentation format you would be verifying against, and the Popular Peptides collection covers the compounds most wholesale accounts review first.